Anti-Inflammatory Technology

 BIOLOGY OF THE SKIN INFLAMMATORY PROCESS

Inflammatory skin diseases are the most common problem in dermatology. They come in many forms, from occasional rashes accompanied by skin itching and redness to chronic conditions such as dermatitis (eczema), rosacea, seborrheic dermatitis, and psoriasis. Skin inflammation, which is characterized by redness, swelling, heat, itching and pain, can exist in either an acute or chronic form with acute disease frequently progressing to a more chronic condition.   Acute inflammation can result from exposure to UV radiation (UVR), ionizing radiation, allergens, or to contact with chemical irritants (soaps, hair dyes, etc.). Assuming that the triggering stimulus is eliminated, this type of inflammation is typically resolved within 1 to 2 weeks with little accompanying tissue destruction. A chronic inflammatory condition, however, can last a lifetime, and cause considerable damage to the skin. A typical cutaneous inflammatory response and the key cytokines and adhesion molecules expressed during this reaction is illustrated here Cutaneous Inflammation Illustration.

Within minutes of exposure of skin to an insult there is a rapid release of inflammatory mediators from keratinocytes and fibroblasts and from afferent neurons. In response to a triggering stimulus, keratinocytes produce a number of inflammatory mediators including PGE-2 and TNF-alpha as well as the cytokines, IL-1, IL-6 and IL-8.  Dermal fibroblasts also respond to the insult and to IL-1 produced by keratinocytes by increasing production and secretion of cytokines including IL-1, IL-6, IL-8 as well as PGE-2. One of the principal actions of PGE-2 produced and secreted by both keratinocytes and fibroblasts is to increase vasodilation and vascular permeability. In addition, PGE-2 aids in the degranulation of mast cells and increases the sensitivity of afferent neuronal endings. The increased sensitivity of nerve ending by prostaglandins and cytokines results in the release of neuropeptides, including substance P and calcitonin gene related peptide (CGRP). Neuron depolarization also increases resulting in the sensation of itching and pain. Substance P and Calcitonin Gene Related Peptide (CGRP) released by neurons, along with PGE-2, cause degranulation and release of histamine from mast cells (ITCHING, SWELLING), and they also stimulates the cell to produce a variety of inflammatory cytokines. If IgE is bound to its receptor on mast cells, exposure of skin to an IgE specific antigen can also trigger the degranulation and activation of the mast cell. Increased vasodilation and vascular permeability by PGE-2 and histamine leads to increased blood flow and extravasation of fluid from blood vessels. This causes visible redness and swelling in the inflamed area. The increased production of inflammatory mediators by keratinocytes and fibroblasts, particularly TNF-alpha and IL-1, leads to the expression of intracellular adhesion molecules, such as VCAM and ICAM, on endothelial cells of the blood vessels.  These proteins, as well as P and E selectin, serve as anchoring elements for monocytes and neutrophils passing through the blood. The attachment of these leukocytes to the adhesion molecules slows their movement through the bloodstream and finally causes their firm adhesion to the endothelial wall. In the presence of chemokines, particularly, IL-8 produced and released by both keratinocytes and fibroblasts, the adherent leukocytes undergo chemotaxis and migrate from the blood vessel out into the skin where they act to scavenge the area of debris and also produce additional inflammatory mediators. The initial acute response occurs within minutes of the insult to the skin and involves the production of inflammatory mediators, the degranulation of mast cells and the vasodilation of blood vessels. The subsequent movement of neutrophils and monocytes into the “wounded” area typically takes up to 48 hours to occur. If the triggering stimulus is eliminated, inflammatory mediator production by keratinocytes, fibroblasts and mast cells ceases, the influx of leukocytes to the “wounded” area decreases and inflammation subsides.

In contrast to acute inflammation which typically resolves in 1 to 2 weeks, chronic inflammation (for example, PSORIASIS) results from a sustained immune cell mediated inflammatory response within the skin itself and is long-lasting. Antigen presenting cells (APC) in the skin, called Langerhans cells in the epidermis and dendritic cells (DC) in the dermis, can be activated by innate mechanisms and by exposure to the inflammatory cytokines, IL-1 and TNF-alpha, produced by fibroblasts and keratinocytes in response to a triggering stimulus. The activated APCs bind to and transport skin antigens (allergens) through the lymphatics during which time they undergo a maturation process. This maturation step allows the APCs to efficiently present the antigen to T lymphocytes. This presentation, in turn, triggers the maturation of a specific subset of naïve T-lymphocytes into memory cells and the activation of resident antigen specific T-lymphocytes. The “skin-homing T-lymphocytes, which express a cell surface epitope, termed CLA (cutaneous lymphocyte antigen), migrate to the involved area of skin, adhere to endothelial cell walls initially through an interaction between the CLA expressed on the surface of the T-lymphocyte and E selectin expressed on endothelial cells. Other specific receptors on T-lymphocytes, which aid in the binding and chemotaxis of these cells into the skin, include CCR4 and LFA1. Once T-lymphocyes have migrated into the skin from the circulation, they not only undergo proliferation, but also produce and secrete a wide range of inflammatory mediators as well as matrix-eroding enzymes, such as MMP-1 (matrix metalloproteinase-1; collagenase). Cytokines produced by T-lymphocytes can stimulate fibroblasts and keratinocytes to produce additional cytokines and chemokines, and can also induce the expression of a variety of tissue-destructive enzymes by fibroblasts, including MMP-1 (collagen), MMP-3 (stomelysin-1) and MMP-9 (gelatinase B). As long as the antigen or insult stimulus persists in the skin, the inflammatory response will continue resulting in significant and serious tissue destruction.

 Inflammatory processes in the skin, particularly those triggered by long-term exposure to solar radiation, not only cause the more obvious symptoms of redness, swelling and itching, but also trigger molecular pathways that escalate the aging process. Actinic aging, or photoaging, that occurs following prolonged exposure of the skin to ultraviolet (UV) light from the sun results in increased cytokine production with attendant activation of genes in both keratinocytes and fibroblasts that cause erosion of the normal skin structure. Matrix metalloproteinases (MMPs), which break down the skin extracellular matrix causing sagging and wrinkling, are stimulated in sun-exposed skin. Furthermore, dermal fibroblast synthesis and assembly of collagen, which is required to maintain and restore the extracellular matrix, is inhibited while elastin production is over- stimulated, leading to elastosis. It is now widely accepted that sun-exposed skin in most individuals remains in a constant state of low level UV-induced inflammation, called "smoldering inflammation" and that this leads to accelerated skin aging. 

Based on the knowledge of the critical inflammatory mediators that are expressed by skin cells, and which are involved in the onset or progression of skin disorders such as rosacea, psoriasis, eczema, acne, and even radiation dermatitis, Therametics scientists have developed a proprietary cell and molecular biology based screening strategy (Therascreen) to identify novel botanically-derived compounds that suppress inflammatory responses in cultured skin cells (keratinocytes and fibroblasts), and immune cells (monocytes and T- lymphocytes).

The screening strategy has several steps. First, each candidate anti-inflammatory compound is tested for its ability to block several key inflammatory mediators and adhesion molecules produced in the skin. Compounds that pass this screening are further analyzed for their ability to block the gene activity of these key same inflammatory mediators and adhesion molecules.  A final screen determines the specific effect of each bioactive compound on the activity of over 100 inflammatory cytokines using antibody array technology. A diagram of one of the several screening strategies Therametics scientists use for identifying new anti-inflammatory drug candidates in skin cells can be seen by clicking this link. 

As can be seen in this schematic diagram, Therascreen analysis is used to screen compounds for their ability to block inflammatory cytokine production in immune cells as well as skin cells.

This screening approach has led to the identification of several novel botanically derived chemical compounds with pronounced anti-inflammatory and anti-aging activities. Therosol® is the leading Therametics anti-inflammatory compound.  This patent pending compound has been shown in cell culture to block the production of a wide number of inflammatory cytokines from keratinocytes, fibroblasts and monocytes.  As a result of blocking these inflammatory processes in the skin, Therametics compounds may be able to effectively treat a variety of inflammatory symptoms including:

  • Reducing and even blocking sun-induced erythema (sunburn)
  • Halting the progression of sunburn and accelerating the recovery of the skin from sunburn
  • Relieving the symptoms of many forms of dermatitis, including radiation dermatitis.
  • Relieving the symptoms of rosacea.
  • Reducing the severity of eczema.
  • Reducing itching, swelling and redness caused by poison ivy and bug bites.
  • Reduce the redness and uneven complexion caused by acne.
  • Relieving the symptoms of psoriasis.

Further, studies have shown that Therosol® is able to block redness caused by exposure of human skin to ultraviolet radiation.

The effect of Therosol on the various inflammatory pathways can be seen in this inflammatory cartoon by clicking here. Blue circles with X's represent direct inhibitory effects of Therosol on inflammation while red circles with X's show indirect inhibitory effects of Therosol on inflammation. 

 

To order or learn more about products that contain Therosol®, Click here.

 
Site powered by: Custom Web Designs.biz